SWOG clinical trial number
CTSU/E7208

A Randomized Phase II Study of Irinotecan and Cetuximab with or without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy

Closed
Phase
Abbreviated Title
Rando Ph II Irino+Cetux +/- Ramucirumab KRAS WT CRC
Status Notes
Closed to accrual effective 7/7/17
Activated
07/01/2014
Closed
07/07/2017
Participants
CTSU

Research committees

Gastrointestinal Cancer

Treatment

Irinotecan Cetuximab Ramucirumab

Publication Information Expand/Collapse

2018

Randomized trial of Irinotecan and Cetuximab (IC) verus Irinotecan, Cetuximab and Ramucirumab (ICR) as 2nd line therapy of advanced colorectal cancer (CRC) following Oxaliplatin and Bevacizumab based therapy: Results of E7208

H Hochster;P Catalano;EP Mitchell;DM Cohen;P O'Dwyer;B Faller;J Kortmansky;M O'Hara;S Kircher;J Lacy;HJ Lenz;U Verma;A Benson J Clin Oncol 36, 2018 (suppl; abstr 3504); ASCO Annual Meeting (June 1- 5, 2018, Chicago, IL), oral

Other Clinical Trials

SWOG Clinical Trial Number
S2303

Randomized Phase II/III Trial of 2nd Line Nivolumab + Paclitaxel + Ramucirumab versus Paclitaxel + Ramucirumab in Patients with PD-L1 CPS ≥ 1 Advanced Gastric and Esophageal Adenocarcinoma (PARAMUNE)
Research Committee(s)
Gastrointestinal Cancer
Activated
05/06/2024
Open
SWOG Clinical Trial Number
CTSU/A022101

A Pragmatic Randomized Phase III Trial Evaluating Total Ablative Therapy for Patients with Limited Metastatic Colorectal Cancer: Evaluating Radiation, Ablation, and Surgery (ERASur)
Research Committee(s)
Gastrointestinal Cancer
Activated
01/10/2023
Open
SWOG Clinical Trial Number
S2107

Randomized Phase II Trial of Encorafenib and Cetuximab with or Without Nivolumab (NSC #748726) for Patients with Previously Treated, Microsatellite Stable, BRAFV600E Metastatic and/or Unresectable Colorectal Cancer
Research Committee(s)
Gastrointestinal Cancer
Activated
06/06/2022
Accrual
83%
Open
Phase